- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04354246
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
February 10, 2024 updated by: Compugen Ltd
A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
- Drug: Dose escalation: COM902 monotherapy.
- Combination product: Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)
- Drug: Cohort expansion: COM902 (RDFE) monotherapy.
- Drug: Cohort expansion: COM902 in combination with COM701 (both at the RDFE).
- Combination product: Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Study Type
Interventional
Enrollment (Estimated)
110
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lead COM902 ClinInfo
- Phone Number: +1 415 373 0781
- Email: COM902-001@cgen.com
Study Contact Backup
- Name: Backup COM902 ClinInfo
- Phone Number: +1 415 373 0781
- Email: COM902-001@cgen.com
Study Locations
-
-
Florida
-
Sarasota, Florida, United States, 34230
- Recruiting
- Florida Cancer Specialists
-
Contact:
- COM902 Study Director
- Phone Number: 415-373-0781
- Email: COM902-001@cgen.com
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital.
-
Contact:
- COM902 Study Director
- Phone Number: 415-373-0781
- Email: COM902-001@cgen.com
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- START Midwest.
-
Contact:
- COM902 Study Director
- Phone Number: 415-373-0781
- Email: COM902-001@cgen.com
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- The Ohio State University Comprehensive Cancer Center.
-
Contact:
- COM902 Study Director
- Phone Number: 415-373-0781
- Email: COM902-001@cgen.com
-
-
Tennessee
-
Memphis, Tennessee, United States, 38138
- Recruiting
- The University of Tennessee WEST Cancer Center.
-
Contact:
- COM902 Study Director.
- Phone Number: 415-373-0781
- Email: COM902-001@cgen.com
-
-
Texas
-
Dallas, Texas, United States, 75230
- Recruiting
- Mary Crowley Cancer Research
-
Contact:
- COM902 Study Director.
- Phone Number: 415-373-0781
- Email: COM902-001@cgen.com
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center.
-
Contact:
- COM902 Study Director
- Phone Number: 415-373-0781
- Email: COM902-001@cgen.com
-
San Antonio, Texas, United States, 78229
- Recruiting
- The START Center for Cancer Care.
-
Contact:
- COM902 Study Director
- Phone Number: 415-373-0781
- Email: COM902-001@cgen.com
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Froedtert & Medical College of Wisconsin
-
Contact:
- COM902 Study Director
- Phone Number: 415-373-0781
- Email: COM902-001@cgen.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Subjects with histologically/cytologically confirmed advanced malignancy (solid tumor) who must have exhausted all available standard therapy, or not a candidate for standard therapy.
- Subject is able to provide written, informed consent before initiation of any study related procedures, and is able, in the opinion of the investigator, to comply with all the requirements of the study.
- Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
For Triplet combination MSS-CRC:
- Histologically confirmed adenocarcinoma of the colon/rectum
- Stage IV disease
- MSS-CRC status by an FDA approved test
- Disease progression with no more than 3 prior lines of treatment including fluroropyrimidines, irinotecan, and oxaliplatin
For Triplet combination ovarian cancer:
- Advanced epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
- Platinum resistant ovarian cancer (PROC) defined as disease recurrence < 6 months after completion of a platinum-containing regimen: Patients with primary platinum refractory disease are ineligible. Primary platinum refractory disease is defined as progression of disease prior to completion of 1st line platinum therapy or immediately following (≤ 3 months following last date of chemotherapy)
- Received ≤3 prior lines for PROC; maintenance bevacizumab or PARP are not included as a line of therapy
- Subjects who have received PARP inhibitor therapy are eligible
Key Exclusion Criteria:
- Prior treatment with a TIGIT inhibitor.
- Prior treatment with an inhibitor of PVRIG
- Symptomatic interstitial lung disease or inflammatory pneumonitis.
- History of immune-related events that required immunotherapy treatment discontinuation
For Triplet combination expansion cohorts (MSS-CRC and PROC): Prior treatment with an anti-PD-1/PD-L1/2, anti-CD96 antibody, anti-OX-40 antibody, anti-CD137 antibody, anti-LAG3, anti-TIM3, anti-CTLA4 antibody.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: COM902 monotherapy dose escalation.
Monotherapy dose escalation.
COM902 monotherapy administered IV every 3 weeks in sequential dose escalation.
Up to 7 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended dose for expansion (RDFE) is identified.
|
COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.
|
Experimental: Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE).
COM902 will be combined with COM701 for evaluation of safety and tolerability.
All study drugs will be administered IV every 3 weeks.
|
Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability.
All study drugs will be administered IV every 3 weeks.
|
Experimental: COM902 monotherapy cohort expansion at RDFE.
COM902 monotherapy at the RDFE - in subjects with multiple myeloma.
COM902 will be administered IV every 3 weeks.
|
COM902 monotherapy (RDFE) in subjects with multiple myeloma.
COM902 will be administered IV every 3 weeks.
|
Experimental: COM902 + COM701 combination cohort expansion both at RDFE.
COM902 + COM701 (both at the RDFE) evaluated in subjects with select tumor types who have exhausted standard of care treatment: HNSCC, CRC (MSS), NSCLC.
All study drugs will be administered IV every 3 weeks.
|
COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC.
All study drugs will be administered IV every 3 weeks.
|
Experimental: MSS-CRC Triplet combination (COM902 + COM701 + Pembrolizumab).
Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with MSS-CRC.
All study drugs will be administered IV every 3 weeks.
|
Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.
|
Experimental: Platinum resistant ovarian cancer Triplet combination (COM902 + COM701 + Pembrolizumab).
Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with PROC.
All study drugs will be administered IV every 3 weeks.
|
Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The safety and tolerability of COM902 monotherapy and in combination with COM701.
Time Frame: DLT evaluation window in the 1st cycle (21 Days).
|
Incidence of subjects with Adverse Events (AEs) as per CTCAE v5.0 and Dose-Limiting Toxicities (DLTs).
|
DLT evaluation window in the 1st cycle (21 Days).
|
To identify the maximum tolerated dose (MTD) and/or recommended dose for expansion of COM902 monotherapy and in combination with COM701.
Time Frame: 18 months.
|
Evaluation of a dose of COM902 monotherapy and in combination with COM701 that is well tolerated by subjects.
|
18 months.
|
To characterize the pharmacokinetic (PK) profile of COM902 as monotherapy and in combination with COM701.
Time Frame: 18 months.
|
Evaluation of parameters of COM902 monotherapy or in combination with COM701 exposure such as Maximum Plasma Concentration [Cmax]).
|
18 months.
|
Evaluation of safety and tolerability of the Triplet combination (COM902 + COM701 + Pembrolizumab).
Time Frame: 18 months.
|
Incidence of subjects on the Triplet combination (COM902 + COM701 + Pembrolizumab) with Adverse Events (AEs) per CTCAE v5.0.
|
18 months.
|
Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).
Time Frame: 18 months.
|
Evaluation of PK parameters e.g., Cmax.
|
18 months.
|
Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).
Time Frame: 18 months.
|
Evaluation of PK parameters e.g., AUC.
|
18 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To characterize immunogenicity of COM902 monotherapy and in combination with COM701.
Time Frame: 18 months.
|
Evaluation of anti drug antibody to COM902 (monotherapy) or COM902, COM701 when administered in combination.
|
18 months.
|
To characterize the immunogenicity of the Triplet combination (COM902 + COM701 + Pembrolizumab).
Time Frame: 18 months.
|
Evaluation of antidrug antibody to COM902, COM701.
|
18 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the preliminary antitumor activity of COM902 as monotherapy and in combination with COM701.
Time Frame: 24 months.
|
An assessment of preliminary antitumor activity eg ORR with COM902 monotherapy and COM902 in combination with COM701.
|
24 months.
|
Preliminary antitumor activity of the triplet combination (COM902 + COM701 + Pembrolizumab).
Time Frame: 24 months
|
Assessment of preliminary antitumor activity e.g., ORR.
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: COM902 Study Director COM902 Study Director, Compugen Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 31, 2020
Primary Completion (Estimated)
December 30, 2024
Study Completion (Estimated)
March 30, 2025
Study Registration Dates
First Submitted
April 15, 2020
First Submitted That Met QC Criteria
April 16, 2020
First Posted (Actual)
April 21, 2020
Study Record Updates
Last Update Posted (Estimated)
February 13, 2024
Last Update Submitted That Met QC Criteria
February 10, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Neoplasms by Site
- Hematologic Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Hemorrhagic Disorders
- Colonic Diseases
- Intestinal Diseases
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Intestinal Neoplasms
- Rectal Diseases
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Colorectal Neoplasms
- Plasmacytoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- CPG-02-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Dose escalation: COM902 monotherapy.
-
University of California, San FranciscoNot yet recruitingProstate Adenocarcinoma | Localized Prostate CarcinomaUnited States
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
National Cancer Institute, EgyptRecruitingHead and Neck CancerEgypt
-
Weill Medical College of Cornell UniversityActive, not recruiting
-
Cliniques universitaires Saint-Luc- Université...UnknownHead and Neck CancerBelgium
-
University Hospital OlomoucUniversity Hospital Ostrava; Masaryk Memorial Cancer InstituteRecruitingHypoxia | Head and Neck Cancer | Dose Escalation | FMISOCzechia
-
Royal North Shore HospitalRecruitingPalliative RadiotherapyAustralia
-
Hinova Pharmaceuticals Inc.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
PharmAbcineMerck Sharp & Dohme LLC; Novotech (Australia) Pty LimitedNot yet recruitingAdvanced or Metastatic Solid TumorsAustralia
-
Istituto Clinico HumanitasRecruitingNon Small Cell Lung Cancer | Lung MetastasesItaly